drug
sofetabart mipitecan
Phase 3updated 6mo agoby Eli Lilly and Co
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying sofetabart mipitecan
News(1)
- ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer spaceEli Lilly has shared phase 1 data on an antibody-drug conjugate in platinum-sensitive ovarian cancer, shedding light on the company’s chances of competing for a market targeted by rivals including…fiercebiotech · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that